Ultime notizie per Athira Pharma (NASDAQ:ATHA) Azioni

Athira Pharma

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

Athira Pharma Inc

Atha Energy Corp

Athabasca Minerals Inc

ATHABASCA OIL CORP by Athabasca Oil Corp.

Athabasca Oil Corp

The Consumer Financial Protection Bureau sued three of the nation's largest banks and the operator of Zelle last week, alleging a failure to protect consumers from widespread fraud on the peer-to-peer payment network, resulting in customer losses of more than <a href="https://www.benzinga.com/markets/equities/24/08/40155365/zelle-controversy-heats-up-jpmorgan-considers-legal-action">$870 million since 2017. </a>
The Details: The CFPB's <a href="https://www.consumerfinance.gov/enforcement/actions/early-warning-services-llc-bank-of-america-na-jpmorgan-chase-bank-na-wells-fargo-bank-na/">lawsuit</a> alleges that JP Morgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) and Early Warning Services rushed to complete the Zelle payment network in order to compete with Venmo and CashApp and neglected to enact effective fraud safeguards. 
Read Next: <a href="https://www.benzinga.com/news/24/12/42669113/waymos-autonomous-vehicles-are-safer-than-human-drivers-report">Waymo&#8217;s Autonomous Vehicles Are Safer Than Human Drivers: Report</a>
"The nation's largest banks felt threatened by competing payment apps, so they rushed to put out Zelle," said CFPB Director Rohit Chopra. "By their failing to put in place proper safeguards, Zelle became a gold mine for fraudsters, while often leaving victims to fend for themselves."
The lawsuit further alleges that the banks "systemically failed" their customers by failing to properly investigate customer complaints or share information on known acts of fraud which allowed bad actors to hop between banks and commit repeated fraudulent transactions.&nbsp;
Benzinga contacted JPMorgan, Wells Fargo, Bank of America and Early Warning Services for comment on the lawsuit. 
In <a href="https://www.cbsnews.com/news/zelle-fraud-chase-bank-of-america-wells-fargo-cfpb-payments/">a statement</a> given to CBS News, a Zelle spokesperson said the CFPB&#8217;s accusations are &#8220;legally and factually flawed&#8221; and the lawsuit is &#8220;driven by political factors."&nbsp;
JPMorgan also told CBS News that the CFPB has a &#8220;political agenda,&#8221;and the agency is &#8220;overreaching its authority by making banks accountable for criminals, even including romance scammers.&#8221;
The CFPB said its lawsuit aims to stop the banks' alleged unlawful practices, secure penalties for the violations and obtain other relief for consumers.&nbsp;
"The banks failed to fix glaring flaws in their systems even as hundreds of thousands of customers filed complaints about fraud," Chopra said in a <a href="https://www.consumerfinance.gov/about-us/newsroom/prepared-press-call-remarks-of-cfpb-director-rohit-chopra-on-the-zelle-lawsuit-announcement/">statement</a>.
"The banks knew their customers were having their money stolen, but since they weren't bearing the cost of these losses themselves, they dragged their feet on fixing the problems," he added.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/24/12/42653466/honda-nissan-plan-to-merge-in-the-face-of-chinese-ev-competition">Honda, Nissan Confirm Merger Plans To Offset Chinese EV Competition: How Mitsubishi Factors In</a></li>
</ul>
Image: Shutterstock.

Fintech news covering the emerging Financial Technology services sector

Fintech

Large Cap

News

Legal

Tech

'Zelle Became A Gold Mine For Fraudsters': Consumer Financial Protection Bureau Lawsuit

Coeptis Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) shares traded higher on Thursday after the company announced the completion of its acquisition of the NexGenAI Affiliates Network platform <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/n42682156/coeptis-therapeutics-makes-bold-strides-in-innovation-with-the-acquisition-of-nexgenai-affiliates-" rel="noreferrer noopener">and the launch of Coeptis Technologies.</a>
This new division is designed to diversify the company&#8217;s growth potential, specifically in highly regulated industries like biotech, pharmaceuticals, and multi-level marketing.
The NexGenAI Affiliates Network platform, developed by NexGenAI Solutions Group, is an AI-powered marketing software and robotic process automation (RPA) solution.
This tool helps marketers process large volumes of data, optimize campaigns, improve customer engagement, and streamline operations—key factors for success in the competitive and regulated sectors Coeptis serves.
Also Read:<a target="_blank" href="https://www.benzinga.com/24/12/42686387/sealsq-launches-sealquantumcom-lab-to-help-businesses-transition-to-quantum-safe-encryption" rel="noreferrer noopener"> SEALSQ Launches SEALQUANTUM.com Lab To Help Businesses Transition To Quantum-Safe Encryption</a>
Dave Mehalick, President and CEO of Coeptis, highlighted that integrating these AI-driven tools will be crucial for optimizing marketing strategies and driving measurable results in industries where competition and regulatory challenges are intense.
Anshuman Dash, Lead Advisor behind the NexGenAI platform, emphasized that this acquisition aligns with Coeptis&#8217; mission to revolutionize marketing and operational efficiency in the biopharmaceutical sector.
By leveraging advanced AI and RPA technologies, Coeptis aims to enhance its service offerings and provide innovative solutions to overcome marketing challenges in the biotech, pharma, and MLM sectors, setting the stage for future growth.
Price Action: COEP shares are trading higher by 45.8% to $0.2070 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42682230/tech-bull-predicts-26-upside-for-apple-stock-sees-golden-era-of-growth-for-cupertino-due-to-multi-year-ai-driven-iphone-upgrade-cycle" target="_blank" rel="noreferrer noopener">Tech Bull Predicts 26% Upside For Apple Stock, Sees &#8216;Golden Era Of Growth&#8217; For Cupertino Due To Multi-Year AI-Driven iPhone Upgrade Cycle</a></li>
</ul>
Photo via Shutterstock.

Equities

Markets

Movers

General

COEP

Why Is Penny Stock Coeptis Therapeutics Gaining Today?

Investors with a lot of money to spend have taken a bearish stance on KULR Tech Gr (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/KULR#AMEX">KULR</a>).
And retail traders should know.
We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with KULR, it often means somebody knows something is about to happen.
Today, Benzinga's options scanner spotted 8 options trades for KULR Tech Gr.
This isn't normal.
The overall sentiment of these big-money traders is split between 37% bullish and 50%, bearish.
Out of all of the options we uncovered, there was 1 put, for a total amount of $29,250, and 7, calls, for a total amount of $484,110.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $0.5 to $7.5 for KULR Tech Gr during the past quarter. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of KULR Tech Gr stands at 5317.0, with a total volume reaching 11,309.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in KULR Tech Gr, situated within the strike price corridor from $0.5 to $7.5, throughout the last 30 days.
<h3>KULR Tech Gr Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735228836_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>KULR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$3.4</td>
<td>$3.0</td>
<td>$3.0</td>
<td>$0.50</td>
<td>$180.0K</td>
<td>6.6K</td>
<td>1.0K</td>
</tr>
<tr>
<td>KULR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.0</td>
<td>$0.95</td>
<td>$1.05</td>
<td>$5.00</td>
<td>$60.7K</td>
<td>11.3K</td>
<td>4.0K</td>
</tr>
<tr>
<td>KULR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$1.2</td>
<td>$1.05</td>
<td>$1.09</td>
<td>$4.00</td>
<td>$55.3K</td>
<td>1.5K</td>
<td>504</td>
</tr>
<tr>
<td>KULR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$1.85</td>
<td>$1.55</td>
<td>$1.8</td>
<td>$7.50</td>
<td>$54.0K</td>
<td>7.0K</td>
<td>1.6K</td>
</tr>
<tr>
<td>KULR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$4.2</td>
<td>$4.1</td>
<td>$4.2</td>
<td>$0.50</td>
<td>$49.9K</td>
<td>6.6K</td>
<td>1.8K</td>
</tr>
</tbody>
</table>

<h3>About KULR Tech Gr</h3>
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems; artificial intelligence and Cloud computing; energy storage; and 5G communication technologies.
After a thorough review of the options trading surrounding KULR Tech Gr, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>KULR Tech Gr's Current Market Status</h3>
<ul>
<li>With a trading volume of 53,166,158, the price of KULR is up by 31.88%, reaching $4.51.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 106 days from now.</li>
</ul>
<h3>What Analysts Are Saying About KULR Tech Gr</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $5.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Benchmark has elevated its stance to Buy, setting a new price target at $5. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for KULR Tech Gr with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

KULR

Spotlight on KULR Tech Gr: Analyzing the Surge in Options Activity

Deep-pocketed investors have adopted a bearish approach towards CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CVS usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for CVS Health. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 45% leaning bullish and 54% bearish. Among these notable options, 8 are puts, totaling $587,869, and 3 are calls, amounting to $211,402.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $40.0 and $55.0 for CVS Health, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for CVS Health's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across CVS Health's significant trades, within a strike price range of $40.0 to $55.0, over the past month.
<h3>CVS Health Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735228831_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$13.85</td>
<td>$13.7</td>
<td>$13.85</td>
<td>$55.00</td>
<td>$191.1K</td>
<td>18.5K</td>
<td>1.8K</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$14.75</td>
<td>$13.85</td>
<td>$14.42</td>
<td>$55.00</td>
<td>$181.6K</td>
<td>18.5K</td>
<td>0</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$5.85</td>
<td>$5.75</td>
<td>$5.75</td>
<td>$40.00</td>
<td>$108.6K</td>
<td>261</td>
<td>302</td>
</tr>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$6.6</td>
<td>$6.5</td>
<td>$6.5</td>
<td>$47.50</td>
<td>$69.5K</td>
<td>812</td>
<td>94</td>
</tr>
<tr>
<td>CVS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$5.85</td>
<td>$5.75</td>
<td>$5.75</td>
<td>$40.00</td>
<td>$63.8K</td>
<td>261</td>
<td>2</td>
</tr>
</tbody>
</table>

<h3>About CVS Health</h3>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
After a thorough review of the options trading surrounding CVS Health, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Current Position of CVS Health</h3>
<ul>
<li>Trading volume stands at 2,561,563, with CVS's price up by 2.01%, positioned at $45.14.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 41 days.</li>
</ul>
<h3>Professional Analyst Ratings for CVS Health</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $66.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a positive move, an analyst from Deutsche Bank has upgraded their rating to Buy and adjusted the price target to $66. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for CVS Health, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Market Whales and Their Recent Bets on CVS Options

Whales with a lot of money to spend have taken a noticeably bearish stance on Celsius Holdings.
Looking at options history for Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 25% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $302,702 and 3, calls, for a total amount of $152,625.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $20.0 and $60.0 for Celsius Holdings, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Celsius Holdings's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Celsius Holdings's whale activity within a strike price range from $20.0 to $60.0 in the last 30 days. 
<h3>Celsius Holdings Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735228826_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$33.75</td>
<td>$32.3</td>
<td>$32.9</td>
<td>$60.00</td>
<td>$164.5K</td>
<td>802</td>
<td align="right">50</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$8.0</td>
<td>$7.4</td>
<td>$7.8</td>
<td>$20.00</td>
<td>$78.0K</td>
<td>15.5K</td>
<td align="right">100</td>
</tr>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$33.15</td>
<td>$32.45</td>
<td>$32.91</td>
<td>$60.00</td>
<td>$42.7K</td>
<td>802</td>
<td align="right">64</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$11.45</td>
<td>$11.15</td>
<td>$11.3</td>
<td>$27.50</td>
<td>$38.4K</td>
<td>361</td>
<td align="right">50</td>
</tr>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$33.15</td>
<td>$32.45</td>
<td>$32.93</td>
<td>$60.00</td>
<td>$36.2K</td>
<td>802</td>
<td align="right">75</td>
</tr>
</tbody>
</table>

<h3>About Celsius Holdings</h3>
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 96% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages, Celsius Essentials line (containing aminos), and Celsius On-the-Go powder packets. Celsius dedicates its efforts to branding and innovation, while it utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.
<h3>Current Position of Celsius Holdings</h3>
<ul>
<li>Trading volume stands at 1,083,259, with CELH's price down by -0.18%, positioned at $27.31.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 63 days.</li>
</ul>
<h3>Expert Opinions on Celsius Holdings</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $37.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Needham downgraded its action to Buy with a price target of $38. 
&#x2A; An analyst from Morgan Stanley persists with their Equal-Weight rating on Celsius Holdings, maintaining a target price of $42. 
&#x2A; An analyst from JP Morgan downgraded its action to Overweight with a price target of $37. 
&#x2A; An analyst from Deutsche Bank downgraded its action to Hold with a price target of $32. 
&#x2A; Maintaining their stance, an analyst from Roth MKM continues to hold a Buy rating for Celsius Holdings, targeting a price of $38. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Celsius Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

CELH

Spotlight on Celsius Holdings: Analyzing the Surge in Options Activity

The statistics aren&#8217;t kind. Eighty percent of pro athletes go broke soon after retiring. <a href="https://www.benzinga.com/general/sports/24/11/41918005/super-bowl-lix-betting-odds-kansas-city-chiefs-favorite-to-three-peat-can-detroit-lions-spoil-the-party-make-team-history">Kansas City Chiefs</a>&#8216; Marquise &#8220;Hollywood&#8221; Brown will not be among them. Despite NFL stars&#8217; eight-figure contracts, in most cases, their financial literacy does not match their salaries. Brown wants to change that.&nbsp;
&#8220;Players often leave their finances up to financial advisers who tend to invest in more traditional avenues, like stocks, because those methods also earn money for the advisers,&#8221; Brown told Mansion Global.
Don't Miss:
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/connect-invest-real-estate-notes">These high-yield real estate notes that pay 7.5% &#8211; 9% make earning passive income easier than ever.</a></li>
<li>This Jeff Bezos-backed startup will allow you to <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">become a landlord in just 10 minutes, with minimum investments as low as $100 for properties like the Byer House from Stranger Things.</a></li>
</ul>
&#8220;It hurts, seeing the stories of these guys who end up with nothing,&#8221; he said. &#8220;It&#8217;s a problem within the <a href="https://www.benzinga.com/general/sports/24/12/42512587/netflix-analyst-say-its-only-investable-media-stock-projects-150-million-nfl-christmas-day-boost">NFL</a>, specifically for guys like myself who come from a background without a lot of money. We&#8217;re not educated on how to handle finances,&#8221; Brown, who has earned $25 million during a five-year career, continued.
<h2 class="wp-block-heading">A Private Equity Real Estate Firm</h2>
The Kansas City Chiefs wide receiver, who was first drafted to the NFL in 2019 – first playing for the Arizona Cardinals and Baltimore Ravens before signing with the Chiefs this year – has cofounded Platinum Pro Capital, a private equity real estate firm with his wife, real estate influencer Zoei Brown. The firm has joined Jason Caraway of Island Sky Investments to educate professional athletes on the advantages of <a href="https://www.benzinga.com/markets/24/12/42484255/seven-of-the-nations-top-10-luxury-listings-are-in-florida-but-trouble-brews-for-landlords">luxury real estate</a> investing – in their case – in the Caribbean and other resort areas.&nbsp;
See Also: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
<h2 class="wp-block-heading">Resort Investing With Added Advantages</h2>
According to Bloomberg, the company has backed an oceanfront luxury condo development in the U.S. Virgin Islands, is renovating a resort in Grand Bahama Island and is planning other projects in <a href="https://www.benzinga.com/content/42532810/61st-coconut-grove-arts-festival-returns-presidents-day-weekend-2025-with-first-horizon-bank-as-pres">South Florida</a> and Costa Rica.
Player investors are not urged to buy high-end rental properties from Brown&#8217;s company. Rather, they invest in his fund passively for returns on their money and the option to stay in vacation properties for free during the off-season.&nbsp;
&#8220;A lot of guys in our field, they like luxurious things, they are drawn to attractive places,&#8221; Brown said. &#8220;And a lot of us travel in the offseason, so instead of having a traditional house, they are drawn to places that feel like a vacation. That&#8217;s appealing to guys. I feel like it creates a sense of unity. So, owning property on Caribbean islands saves money in the long term because that&#8217;s where everybody wants to travel in the offseason. It really caught the eye of a lot of people.&#8221;
Trending: Unlock the hidden potential of commercial real estate —<a href="https://www.benzinga.com/money/marcus-millichap-backed-platform-makes-it-easy-to-invest-in-real-estate"> This platform allows individuals to invest in commercial real estate offering a 12% target yield with a bonus 1% return boost today!</a>
<h2 class="wp-block-heading">Brown&#8217;s Kansas Teammate Is Also An Avid Real Estate Investor</h2>
Of course, Marquise Brown isn&#8217;t the only NFL player with a penchant for real estate investing. Many players invest individually or as a group with other players. In fact, Brown&#8217;s teammate at Kansas, Justin Watson, is an investor in Teal Henderson&#8217;s Bones Investment Group, which, as of 2023, had 78 active investors, 97% of them athletes in the NFL. Bones Investment Group&#8217;s strategy is different from Brown&#8217;s, however. They invest in commercial buildings with tenants such as Publix, <a href="https://www.benzinga.com/insights/news/24/12/42492211/heres-how-much-1000-invested-in-home-depot-15-years-ago-would-be-worth-today">Home Depot</a>, Target, Burger King, CVS and Walmart.
&#8220;If I can expand these athletes&#8217; horizons and kind of put them out there, you know their work ethic and their drive and their desire,&#8221; Henderson, whose husband is a former college football player and NFL agent, told ESPN, &#8220;they&#8217;re gonna dominate, right? And they&#8217;re just not in the commercial space because no one has given them the exposure and the access to it.&#8221;
Read Next:
<ul>
<li>During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes"> high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses.</a></li>
<li>These five entrepreneurs are worth $223 billion –<a href="https://www.benzinga.com/money/arrived-homes-private-credit-fund"> they all believe in one platform that offers a 7-9% target yield with monthly dividends</a></li>
</ul>

Real Estate

Kansas City Chief's Hollywood Brown Has A Real Estate Investment Company And Wants to Empower Other Athletes To Invest

Following his basketball career, NBA Hall of Famer Kobe Bryant turned to investing in companies like BodyArmor and may have been helped on this new career path by<a href="https://www.benzinga.com/general/education/24/06/39547388/happy-birthday-elon-musk-53-facts-and-figures-about-tesla-spacex-ceo-on-his-53rd-birthday"> billionaire Elon Musk.</a>
What Happened: Bryant spoke highly of Musk during an appearance at a 2017 convenience store trade show promoting BodyArmor, a beverage brand <a href="https://www.benzinga.com/news/21/11/23794643/kobe-bryant-bought-10-of-bodyarmor-in-2014-heres-how-much-that-investment-is-worth-now">he invested in</a> back in 2014.
"Elon Musk is I think a genius by all accounts," Bryant said in the interview, as shared by <a href="https://www.youtube.com/watch?v=jSVdxhTEJP4">CNBC</a>.
Bryant praised the commitment and work that Musk put into his companies during the interview. The former NBA star said that he asked Musk one time about how he continues learning.
"The amount of research and the amount of study that he does is unheard of."
Bryant said that Musk shared an important investment lesson with him.
"He will always say the most important thing is imagination."
Bryant shared with the interviewer that imagination could be the key to elevating great ideas beyond merely reading books and studying.
"If you don't have the imagination to then take it to another level, it doesn't mean anything."
Bryant said his conversation with Musk was great and a joy.
The interviewer asked Bryant if this meant he would buy Tesla stock, prompting a great sound bite from the NBA star.
"I'll buy into Elon," Bryant answered.
You may not be a billionaire like Elon Musk, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/general/social-media/24/12/42490690/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">check out five stocks flying under the radar that deserve your attention.</a>
Why It's Important: Bryant died tragically in<a href="https://www.benzinga.com/news/20/01/15186099/nba-legend-kobe-bryant-41-dies-in-helicopter-crash"> a helicopter crash</a> in January 2020 at the age of 41.
In the NBA, Bryant spent 20 seasons with the Los Angeles Lakers, the second-most seasons with a single team in league history.
Bryant's 33,643 points rank fourth all-time and the NBA Hall of Famer holds several records and ranks among the top players of all time. Bryant won five NBA championships during his career and took home four NBA MVP awards and two NBA Finals MVP awards.
After his basketball career, Bryant became an investor in several companies, including BodyArmor. In 2014, Bryant invested $6 million for a 10% stake in the beverage company.
Coca-Cola later acquired full control of BodyArmor in 2021, increasing its existing minority stake in the company. The beverage giant paid $5.6 billion to acquire the remainder of the company valuing BodyArmor at $8 billion.
This meant that Bryant's early stake went from $6 million to $800 million, representing one of the best returns on an investment ever achieved by a former athlete.
Musk's advice for Bryant may have shaped the way he looked at the BodyArmor and other investments.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/23/09/34983022/this-man-helped-make-kobe-bryant-nearly-500m-now-hes-working-with-travis-kelce">This Man Helped Make Kobe Bryant Nearly $500M — Now He&#8217;s Working With Travis Kelce</a></li>
</ul>
Photo: photoyh/Shutterstock.com

Education

Sports

Success Stories

Elon Musk Gave Kobe Bryant 'Genius' Investment Advice In 2017: 'The Most Important Thing Is...'

RPM International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RPM#NYSE">RPM</a>) will release its second-quarter financial results, before the opening bell, on <a href="https://www.benzinga.com/quote/RPM/earnings">Tuesday, Jan. 7, 2025.</a>
Analysts expect the Medina, Ohio-based company to report quarterly earnings at $1.34 per share, up from $1.22 per share in the year-ago period. RPM International projects quarterly revenue of $1.79 billion, compared to $1.79 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Oct. 2, RPM International reported first-quarter results. Sales declined 2.1% Y/Y to $1.97 billion, missing the consensus of $2.015 billion.
RPM International shares fell 0.6% to close at $125.35 on Tuesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/RPM/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Morgan Stanley analyst Vincent Sinisi maintained an Equal-Weight rating and raised the price target from $107 to $125 on Oct. 4. This analyst has an accuracy rate of 73%.</li>
<li>Seaport Global analyst Michael Harrison maintained a Buy rating and increased the price target from $140 to $150 on Oct. 3. This analyst has an accuracy rate of 69%.</li>
<li>Wells Fargo analyst Michael Sison maintained an Equal-Weight rating and increased the price target from $125 to $134 on Oct. 3. This analyst has an accuracy rate of 67%.</li>
<li>JP Morgan analyst Jeffrey Zekauskas maintained a Neutral rating and raised the price target from $120 to $126 on Oct. 3. This analyst has an accuracy rate of 67%.</li>
<li>BMO Capital analyst John McNulty reiterated an Outperform rating and increased the price target from $139 to $149 on Oct. 3. This analyst has an accuracy rate of 61%.</li>
</ul>
Considering buying RPM stock? Here&#8217;s what analysts think:
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42684694/top-2-health-care-stocks-you-may-want-to-dump-this-quarter">Top 2 Health Care Stocks You May Want To Dump This Quarter</a></li>
</ul>

Earnings

Price Target

Analyst Ratings

Trading Ideas

RPM International Gears Up For Q2 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

SMX (Security Matters) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) shares are surging after the company unveiled a groundbreaking integration of its technology <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/ac42681455/smx-integrates-its-proprietary-coating-and-digital-platform-technology-for-nfc-rfid-chip-markings" rel="noreferrer noopener">to mark and protect NFC and RFID chips</a>.
This innovation aims to reduce risks of counterfeiting, tampering, and supply chain vulnerabilities.
The company has embedded its unique markers into the coating of standard NFC and RFID chips, enabling precise authentication and verification throughout their lifecycle.
The proprietary coating not only works with off-the-shelf chips but also enhances durability, performance, and resilience to environmental stressors, potentially extending the lifespan and reliability of the chips.
Additionally, the coating can store data and withstand high temperatures (up to 150°C), providing extra protection against the elements.
SMX envisions its technology benefiting the growing market for wearable and flexible electronics, including smartwatches, fitness trackers, and medical devices, where secure, lightweight, and durable components are essential.
The technology is also well-suited for use in fashion, sports, and activewear, where components need to endure tough conditions like washing, flexing, and exposure to sweat and corrosion.
This month, SMX and Ybyra Capital formed a partnership. This deal positions Brazil to fully leverage its vast resources while implementing advanced technology for supply chain traceability, accountability, and sustainability, showcasing <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/ac42386164/combining-assets-smx-and-ybyr-capital-adds-the-once-missing-link-to-brazils-manufacturing-evoluti" rel="noreferrer noopener">the country&#8217;s commitment to leading global change</a>.
Price Action: SMX shares are up 31.5% at $0.2867 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42684942" target="_blank" rel="noreferrer noopener">SciSparc Shares Skyrocket With AutoMax&#8217;s First JAC Motors Shipment</a></li>
</ul>

Small Cap

SMX Shares Soar On NFC/RFID Chip Protection Tech Integration: Details

LQR House Shares Halted To The Upside; Stock Now Up 87.68%

LQR House Shares Resume Trade

Financial giants have made a conspicuous bearish move on CrowdStrike Holdings. Our analysis of options history for CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) revealed 9 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $203,965, and 5 were calls, valued at $190,991.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $140.0 to $430.0 for CrowdStrike Holdings over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in CrowdStrike Holdings's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to CrowdStrike Holdings's substantial trades, within a strike price spectrum from $140.0 to $430.0 over the preceding 30 days.
<h3>CrowdStrike Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735227935_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$64.85</td>
<td>$63.0</td>
<td>$64.85</td>
<td>$380.00</td>
<td>$64.8K</td>
<td align="right">109</td>
<td align="right">11</td>
</tr>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/31/25</td>
<td>$18.45</td>
<td>$16.8</td>
<td>$17.3</td>
<td>$365.00</td>
<td>$51.9K</td>
<td align="right">56</td>
<td align="right">30</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$26.75</td>
<td>$25.4</td>
<td>$25.9</td>
<td>$430.00</td>
<td>$51.8K</td>
<td align="right">182</td>
<td align="right">20</td>
</tr>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$51.2</td>
<td>$50.75</td>
<td>$51.2</td>
<td>$320.00</td>
<td>$51.2K</td>
<td align="right">154</td>
<td align="right">10</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$244.0</td>
<td>$244.0</td>
<td>$244.0</td>
<td>$140.00</td>
<td>$48.8K</td>
<td align="right">17</td>
<td align="right">2</td>
</tr>
</tbody>
</table>

<h3>About CrowdStrike Holdings</h3>
CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.
Following our analysis of the options activities associated with CrowdStrike Holdings, we pivot to a closer look at the company's own performance.
<h3>Current Position of CrowdStrike Holdings</h3>
<ul>
<li>With a trading volume of 245,017, the price of CRWD is down by -0.05%, reaching $365.62.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 68 days from now.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for CrowdStrike Holdings, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

CRWD

What the Options Market Tells Us About CrowdStrike Holdings

Financial giants have made a conspicuous bearish move on Micron Technology. Our analysis of options history for Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) revealed 37 unusual trades.
Delving into the details, we found 27% of traders were bullish, while 59% showed bearish tendencies. Out of all the trades we spotted, 9 were puts, with a value of $1,735,303, and 28 were calls, valued at $3,002,252.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $77.0 to $160.0 for Micron Technology over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Micron Technology's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Micron Technology's significant trades, within a strike price range of $77.0 to $160.0, over the past month.
<h3>Micron Technology Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735227931_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MU</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$5.3</td>
<td>$5.2</td>
<td>$5.29</td>
<td>$100.00</td>
<td>$1.3M</td>
<td>5.1K</td>
<td>2.5K</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/31/25</td>
<td>$0.73</td>
<td>$0.64</td>
<td>$0.7</td>
<td>$77.00</td>
<td>$488.6K</td>
<td>8</td>
<td>6.9K</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$6.85</td>
<td>$6.75</td>
<td>$6.85</td>
<td>$80.00</td>
<td>$445.2K</td>
<td>1.7K</td>
<td>650</td>
</tr>
<tr>
<td>MU</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$15.1</td>
<td>$14.85</td>
<td>$15.0</td>
<td>$90.00</td>
<td>$337.5K</td>
<td>3.6K</td>
<td>225</td>
</tr>
<tr>
<td>MU</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$26.55</td>
<td>$25.45</td>
<td>$26.18</td>
<td>$90.00</td>
<td>$193.4K</td>
<td>1.6K</td>
<td>40</td>
</tr>
</tbody>
</table>

<h3>About Micron Technology</h3>
Micron is one of the largest semiconductor companies in the world, specializing in memory and storage chips. Its primary revenue stream comes from dynamic random access memory, or DRAM, and it also has minority exposure to not-and or NAND, flash chips. Micron serves a global customer base, selling chips into data centers, mobile phones, consumer electronics, and industrial and automotive applications. The firm is vertically integrated.
<h3>Micron Technology's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 3,694,382, the MU's price is down by -0.84%, now at $88.53. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 83 days.</li>
</ul>
<h3>What Analysts Are Saying About Micron Technology</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $151.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on Micron Technology with a target price of $120. 
&#x2A; An analyst from Rosenblatt has decided to maintain their Buy rating on Micron Technology, which currently sits at a price target of $250. 
&#x2A; An analyst from Stifel persists with their Buy rating on Micron Technology, maintaining a target price of $130. 
&#x2A; An analyst from Stifel has revised its rating downward to Buy, adjusting the price target to $135. 
&#x2A; An analyst from Bernstein persists with their Outperform rating on Micron Technology, maintaining a target price of $120. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Micron Technology with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Micron Technology's Options: A Look at What the Big Money is Thinking

Deep-pocketed investors have adopted a bearish approach towards ARM Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ARM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for ARM Holdings. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 22% leaning bullish and 66% bearish. Among these notable options, 3 are puts, totaling $180,189, and 6 are calls, amounting to $344,910.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75.0 to $250.0 for ARM Holdings over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for ARM Holdings's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ARM Holdings's whale activity within a strike price range from $75.0 to $250.0 in the last 30 days. 
<h3>ARM Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735227926_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$58.45</td>
<td>$57.65</td>
<td>$57.65</td>
<td>$75.00</td>
<td>$144.0K</td>
<td>2.6K</td>
<td align="right">25</td>
</tr>
<tr>
<td>ARM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$121.45</td>
<td>$119.45</td>
<td>$120.34</td>
<td>$250.00</td>
<td>$108.3K</td>
<td>216</td>
<td align="right">1</td>
</tr>
<tr>
<td>ARM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$57.95</td>
<td>$56.95</td>
<td>$56.95</td>
<td>$75.00</td>
<td>$56.9K</td>
<td>2.6K</td>
<td align="right">65</td>
</tr>
<tr>
<td>ARM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$56.9</td>
<td>$56.65</td>
<td>$56.65</td>
<td>$75.00</td>
<td>$56.6K</td>
<td>2.6K</td>
<td align="right">45</td>
</tr>
<tr>
<td>ARM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$120.45</td>
<td>$118.75</td>
<td>$119.86</td>
<td>$250.00</td>
<td>$35.9K</td>
<td>216</td>
<td align="right">17</td>
</tr>
</tbody>
</table>

<h3>About ARM Holdings</h3>
Arm Holdings is the IP owner and developer of the ARM architecture (ARM stands for Acorn RISC Machine), which is used in 99% of the world's smartphone CPU cores, and it also has high market share in other battery-powered devices like wearables, tablets, or sensors. Arm licenses its architecture for a fee, offering different types of licenses depending on the flexibility the customer needs. Customers like Apple or Qualcomm buy architectural licenses, which allows them to modify the architecture and add or delete instructions to tailor the chips to their specific needs. Other clients directly buy off-the-shelf designs from Arm. Off-the-shelf and architectural customers pay a royalty fee per chip shipped.
After a thorough review of the options trading surrounding ARM Holdings, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is ARM Holdings Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 693,623, with ARM's price up by 0.32%, positioned at $132.22.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 41 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest ARM Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Spotlight on ARM Holdings: Analyzing the Surge in Options Activity

LQR House Shares Halted To The Upside; Stock Now Up 58.29%

SES AI Shares Resume Trade

SES AI Shares Halted To The Upside; Stock Now Up 119.72%

WIMI

WiMi Develops Quantum Random Access Memory (QRAM) Architecture Utilizing Quantum Gates To Enhance Computational Efficiency With Superposition And Entanglement For Quantum Computing Environments

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>HC Wainwright &amp; Co. raised Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) price target from $40 to $42. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Buy rating. Anavex Life Sciences shares closed at $10.87 on Tuesday. <a href="https://www.benzinga.com/quote/AVXL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James raised the price target for Kemper Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMPR#NYSE">KMPR</a>) from $75 to $82. Raymond James analyst C. Gregory Peters maintained a Strong Buy rating. Kemper shares closed at $65.25 on Tuesday. <a href="https://www.benzinga.com/quote/KMPR/analyst-ratings">See </a><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">how other analysts view this stock.</a></li>
<li>Needham boosted the price target for ACV Auctions Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACVA#NASDAQ">ACVA</a>) from $26 to $28. Needham analyst Chris Pierce maintained a Buy rating. ACV Auctions shares closed at $21.67 on Tuesday. <a href="https://www.benzinga.com/quote/ACVA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut the price target for PolyPid Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPD#NASDAQ">PYPD</a>) from $14 to $11. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Buy rating. PolyPid shares closed at $2.97 on Tuesday. <a href="https://www.benzinga.com/quote/PYPD/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42669200/wall-streets-most-accurate-analysts-give-their-take-on-3-utilities-stocks-with-over-4-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend Yields</a></li>
</ul>

ACVA

AVXL

KMPR

PYPD

Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday

In the current market session, Academy Sports Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASO#NASDAQ">ASO</a>) share price is at $56.61, after a 2.74% drop. Over the past month, the stock increased by 20.93%, but over the past year, it actually decreased by 9.76%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2024/1735227018_0.png" alt="Past Year Chart" />

<h3>How Does Academy Sports P/E Compare to Other Companies?</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of the 19.34 in the Specialty Retail industry, Academy Sports Inc. has a lower P/E ratio of 9.62. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1735227018_1.png" alt="Guage" />

In conclusion, the price-to-earnings ratio is a useful metric for analyzing a company's market performance, but it has its limitations. While a lower P/E can indicate that a company is undervalued, it can also suggest that shareholders do not expect future growth. Additionally, the P/E ratio should not be used in isolation, as other factors such as industry trends and business cycles can also impact a company's stock price. Therefore, investors should use the P/E ratio in conjunction with other financial metrics and qualitative analysis to make informed investment decisions.

Intraday Update

A Look Into Academy Sports Inc's Price Over Earnings

Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August

06:26 EDT Athira Pharma (ATHA) files $300M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving brea...

Athira Pharma files $300M mixed securities shelf

Athira Pharma (ATHA) announced that results from the Phase 2/3 LIFT-AD clinical trial of fosgonimeton to treat Alzheimer's disease will be presente...

Athira Pharma to present results from Phase 2/3 LIFT-AD trial

Vast Renewables, Theriva Biologics, and Athira Pharma are the 3 Penny Stocks to watch on November 5, 2024, based on&nbsp;TipRanks' Penny Stock Scre...

3 Penny Stocks to Watch Now, 11/5/24

"We are pleased to be continuing the advancement of ATH-1105 as a potential treatment for ALS. This novel, oral, next-generation HGF-modulating dru...

Athira Pharma reports Q3 EPS (75c), consensus (71c)

Athira Pharma GAAP EPS of -$0.75 misses by $0.04

JMP Securities analyst Jason Butler reiterated a Hold rating on Athira Pharma (ATHA – Research Report) today. The company's shares closed yesterday...

JMP Securities Keeps Their Hold Rating on Athira Pharma (ATHA)

Athira Pharma, Inc. ( ($ATHA) ) has released its Q3 earnings. Here is a breakdown of the information Athira Pharma, Inc. presented to its investors...

Athira Pharma Reports Q3 2024 Financial Results

Athira Pharma, Inc. (ATHA) has disclosed a new risk, in the Regulation category. Athira Pharma, Inc. faces significant business risk due to its dep...

Athira Pharma's Regulatory Compliance Challenges Threaten Drug Development Pipeline

Athena Gold upsizes private placement from C$1M to up to C$1.25M

ABUS

AHNR

ALPMF

ALPMY

ANTX

ATHA

BAYRY

BAYZF

BBIO

BMRN

CDTX

CRBU

CVAC

FGEN

GLYC

HLVX

IBRX

INAB

LXRX

PGEN

QURE

RAPT

RHHBY

RLAY

RPTX

SLRN

TOVX

VIRX

VSTE

Biotech

Press Releases

Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)

Health Care

Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer's Disease Patients

Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer's Disease

Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer's Disease-Related Pathology at the Alzheimer's Association International Conference (AAIC) 2024

Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer's Disease

Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Meeting

Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND

Comments

Athira Pharma

Notizie

Ultime notizie per Athira Pharma (NASDAQ:ATHA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO